Richmond Pharmacology

Richmond Pharmacology is a contract research organisation specialising in early phase and first-in-human clinical trials for pharmaceutical and biotech companies.

Operating from hospital-adjacent facilities at London Bridge and St George's University London, the company has conducted over 20% of all UK Phase I studies and holds MHRA Standard and Supplementary Accreditation.

In 2020, it became the first CRO globally to administer LNP CRISPR-Cas9 gene-editing therapy to a human.